Inflammation and Cell Death During Cholestasis: The Evolving Role of Bile Acids

Author:

Woolbright Benjamin L.1,Jaeschke Hartmut2

Affiliation:

1. Department of Urology, University of Kansas Medical Center, Kansas City, KS, USA

2. Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA

Abstract

Cholestasis results in blockage of bile flow whether the point of obstruction occurs extrahepatically or intrahepatically. Bile acids are a primary constituent of bile, and thus one of the primary outcomes is acute retention of bile acids in hepatocytes. Bile acids are normally secreted into the biliary tracts and then released into the small bowel before recirculating back to the liver. Retention of bile acids has long been hypothesized to be a primary cause of the associated liver injury that occurs during acute or chronic cholestasis. Despite this, a surge of papers in the last decade have reported a primary role for inflammation in the pathophysiology of cholestatic liver injury. Furthermore, it has increasingly been recognized that both the constituency of individual bile acids that make up the greater pool, as well as their conjugation status, is intimately involved in their toxicity, and this varies between species. Finally, the role of bile acids in drug-induced cholestatic liver injury remains an area of increasing interest. The purpose of this review is to critically evaluate current proposed mechanisms of cholestatic liver injury, with a focus on the evolving role of bile acids in cell death and inflammation.

Publisher

Cognizant, LLC

Subject

Genetics,Molecular Biology

Reference133 articles.

1. Therapeutic targets for cholestatic liver injury;Expert Opin Ther Targets,2016

2. Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis;Toxicol Appl Pharmacol.,2015

3. Comprehensive review of molecular mechanisms during cholestatic liver injury and cholangiocarcinoma;J Liver,2018

4. Will we ever model PSC?—“It’s hard to be a PSC model!”;Clin Res Hepatol Gastroenterol.,2011

5. A placebo-controlled trial of bezafibrate in primary biliary cholangitis;N Engl J Med.,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3